Glioblastoma Therapeutics Network (GTN; U19 Clinical Trial Required)

The National Cancer Institute (NCI) is seeking applications for research focused on developing novel therapies for adult glioblastoma (GBM) through a Notice of Funding Opportunity (NOFO). The primary objective is to improve GBM treatment by creating effective therapeutic agents capable of crossing the blood-brain barrier and advancing these agents through early-stage clinical testing. The initiative encourages the establishment of a highly collaborative Glioblastoma Therapeutics Network (GTN) consisting of interdisciplinary teams that can manage the drug development process from late preclinical stages and IND studies through to pilot clinical trials in humans. This approach aims to bridge a critical gap in GBM drug development, facilitating seamless transitions from early trials to later-stage clinical evaluations using established NCI mechanisms. Eligible therapeutic agents include completely new drugs or repurposed agents and combinations previously approved for other medical uses, provided they undergo appropriate preclinical validation for GBM. The scope of the program covers the critical transition from preclinical through Phase 0/1 clinical studies, emphasizing collaboration and integration within the network. This funding opportunity falls under the Department of Health and Human Services via the National Institutes of Health, with contact support provided by Dr. Suzanne Forry for inquiries. The program aims to accelerate the development of promising GBM treatments by leveraging multi-disciplinary teams and streamlined trial processes to bring effective therapies closer to clinical application.